Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells.
about
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancerEvaluation of genome-wide chromatin library of Stat5 binding sites in human breast cancerNucleic acid-based approaches to STAT inhibitionSignal transducer and activator of transcription 5A/B in prostate and breast cancersPeptidylarginine Deiminase 3 (PAD3) Is Upregulated by Prolactin Stimulation of CID-9 Cells and Expressed in the Lactating Mouse Mammary GlandS731 in the transactivation domain modulates STAT5b activity.The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cellsIL-15 prolongs CD154 expression on human CD4 T cells via STAT5 binding to the CD154 transcriptional promoter.Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.Roles and regulation of stat family transcription factors in human breast cancer.Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancerNeuronal apoptosis induced by selective inhibition of Rac GTPase versus global suppression of Rho family GTPases is mediated by alterations in distinct mitogen-activated protein kinase signaling cascades.The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activityNanoparticle delivery of a peptide targeting EGFR signalingStructure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.Signal transducer and activator of transcription-5 mediates neuronal apoptosis induced by inhibition of Rac GTPase activity.Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate CancerCombined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians.STAT5A/B gene locus undergoes amplification during human prostate cancer progression.Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.Transcription factors: their potential as targets for an individualized therapeutic approach to cancer.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer.Prolactin regulation of the prostate gland: a female player in a male game.The role of transcription factors in prostate cancer and potential for future RNA interference therapy.Robust gene network analysis reveals alteration of the STAT5a network as a hallmark of prostate cancer.Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.Estimation of High-Dimensional Graphical Models Using Regularized Score Matching.Growth hormone enhances LNCaP prostate cancer cell motility.Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
P2860
Q24677026-D6F04835-0513-4ED3-9ABC-EAD6BF396765Q24804817-0E56C61E-ABFC-43B1-B60F-5C23A5347EEEQ26822830-97796664-CB4C-424B-BE7B-3EF1408FD5A8Q28281791-7656BECB-5D86-4948-98A2-4823DE7FF64BQ28552756-6FE18D99-AA28-4126-968B-B0A8F5AB73CAQ30440935-819EFE01-7FDD-4534-A6A9-357F29300656Q33412361-769A2AD9-4B1A-402C-AFD1-CA885B5055DDQ33497042-6CE6D20A-7B23-4FA0-8E3C-96E3A282469DQ33745272-D5FC2601-8576-48D7-95D0-550035E9E744Q33805578-7F43BC0A-BD7E-4E0F-A4BA-4C967BDC4A2FQ34049838-845085F4-EF72-427E-8AC5-7890B50F8756Q34344798-812AD586-6D13-4828-88DA-309E75DC94DDQ34363785-17C0CE03-DFBA-4776-9F46-2F14C72649C7Q34580343-5D3D9C2B-B71C-4AB0-810C-9C4A277F9EA9Q35012937-E961B977-1C86-42B8-837A-F164F97DF799Q35103357-BE38C414-D7A4-4F7C-8411-C91888C9E2EDQ35186472-887BBE8D-6D2A-435B-8475-94C3D059771FQ35351477-5D49C488-5948-4791-B541-C28DCA7097DFQ35583247-76C6C041-1C3B-4216-B37E-F0A8964ACBBEQ35589627-F62B7182-3B94-4F44-80C4-F4A32E68089EQ35646876-B305F1B7-6F0F-48EF-9A22-F9AC13BBE950Q35685196-CAB337F7-563D-44F9-9CC3-1292AE56D97DQ35956715-7BE08D3B-66A6-4052-8469-249B9E26B812Q36134471-587C74E3-3C9E-43C2-9768-73C094A687CEQ36220747-6B7E4524-BCCB-48B9-942E-71145DECA408Q36343768-9595A298-CC2B-4577-9E50-C6A71EAE5173Q36859140-10FF72E5-445C-4C8D-BA6D-3C9B2DE5AB1EQ36888336-A09BE696-6BE2-4C83-B91B-E3AF57D7BE9AQ36908890-CE7EF506-F9BA-4DF0-BC2E-C4B2A7263BA3Q36944559-02E7EEC0-1192-4704-93A9-F0EC92E8845AQ37290948-BB9025AC-4692-4A7F-99E6-7CDA79ADCA2BQ37709535-89450430-7DF0-446C-90B6-EAFE0600A949Q37854477-86DED39B-05A7-4D0A-AB28-E102CC174DA9Q37942413-DE03B267-A9BB-4520-A651-19D026D222D9Q38198726-DAB3E22E-E4E6-4A3D-ABEF-47D94973574CQ38342896-A72D5486-63D8-47E9-A566-E81B16494022Q38385340-E0A85AF2-CDFF-414A-AF0C-D3EA660DE546Q38714794-260D3C69-3111-4181-B34F-3492722F99B6Q38946533-A15EDB69-39A8-4C68-B331-0388F747A88DQ39016653-1D4331EA-B28E-4038-8BB2-169A3EA66BE3
P2860
Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Inhibition of transcription fa ...... f human prostate cancer cells.
@en
type
label
Inhibition of transcription fa ...... f human prostate cancer cells.
@en
prefLabel
Inhibition of transcription fa ...... f human prostate cancer cells.
@en
P2093
P2860
P356
P1476
Inhibition of transcription fa ...... f human prostate cancer cells.
@en
P2093
Hallgeir Rui
Jianqiong Zhu
Jianwu Xie
Kalle Alanen
Marja T Nevalainen
Martti Nurmi
Matthew J LeBaron
Tommi J Ahonen
P2860
P304
27287-27292
P356
10.1074/JBC.M304307200
P407
P577
2003-04-28T00:00:00Z